Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.51 |
| ▸ | FNTA | P49354 | 8/20 | 0.47 |
| ▸ | FNTB | P49356 | 8/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 6/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7653501 | 0.93 | FNTA (0.48) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7656235 | 0.91 | FNTA (0.48) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7654486 | 0.88 | CYP11B1 (0.45) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7656322 | 0.87 | FNTA (0.44) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7655477 | 0.85 | FNTA (0.56) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7656246 | 0.85 | FNTA (0.48) | FNTAFNTBPGGT1B | |
| SCHEMBL7658529 | 0.83 | FNTA (0.43) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7658522 | 0.83 | FNTA (0.55) | FNTAFNTBPGGT1BHDAC6 | |
| SCHEMBL7654002 | 0.80 | HDAC6 (0.51) | CYP11B1CYP11B2FNTAFNTBPGGT1B | |
| SCHEMBL7658616 | 0.78 | FNTA (0.46) | CYP11B1CYP11B2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6384061-B1 | HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS | LG CHEMICAL LTD. (KR) | 2002-05-07 | — | — | US | claimed |
| US-6384061-B1 | HYDANTOIN COMPOUNDS REPRESENTED BY FORMULA (I) WHICH SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE, AND THUS CAN BE USED AS AN ANTI-CANCER AGENT, OR PHARMACEUTICALLY ACCEPTABLE SALTS | LG CHEMICAL LTD. (KR) | 2002-05-07 | — | — | US | disclosed |